135 related articles for article (PubMed ID: 3410341)
1. Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro.
Karlan BY; Amin W; Band V; Zurawski VR; Littlefield BA
Gynecol Oncol; 1988 Sep; 31(1):103-12. PubMed ID: 3410341
[TBL] [Abstract][Full Text] [Related]
2. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
Moser TL; Young TN; Rodriguez GC; Pizzo SV; Bast RC; Stack MS
Int J Cancer; 1994 Feb; 56(4):552-9. PubMed ID: 8112891
[TBL] [Abstract][Full Text] [Related]
3. Characterization of plasminogen activator from two human renal carcinoma cell lines.
Nelson NF; Cieplak W; Dacus SC; Prager MD
J Cell Physiol; 1986 Mar; 126(3):435-43. PubMed ID: 2419348
[TBL] [Abstract][Full Text] [Related]
4. Effect of retinoic acid on human neuroblastoma: correlation between morphological differentiation and changes in plasminogen activator and inhibitor activity.
Benjamin LA; McGarry RC; Hart DA
Cancer Chemother Pharmacol; 1989; 25(1):25-31. PubMed ID: 2590998
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous stimulation of urokinase and tissue-type plasminogen activators by phorbol esters in human ovarian carcinoma cells.
Band V; Karlan BY; Zurawski VR; Littlefield BA
J Cell Physiol; 1989 Jan; 138(1):106-14. PubMed ID: 2492025
[TBL] [Abstract][Full Text] [Related]
6. Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines.
Sitrin RG; Gyetko MR; Kole KL; McKeever P; Varani J
Cancer Res; 1990 Aug; 50(16):4957-61. PubMed ID: 2379161
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators and their inhibitors in the neuromuscular system: I. Developmental regulation of plasminogen activator isoforms during in vitro myogenesis in two cell lines.
Festoff BW; Rao JS; Maben C; Hantaï D
J Cell Physiol; 1990 Aug; 144(2):262-71. PubMed ID: 2199466
[TBL] [Abstract][Full Text] [Related]
8. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.
Young TN; Rodriguez GC; Moser TL; Bast RC; Pizzo SV; Stack MS
Am J Obstet Gynecol; 1994 May; 170(5 Pt 1):1285-96. PubMed ID: 8178854
[TBL] [Abstract][Full Text] [Related]
9. Hormonal and immunological characterization of the cell-associated plasminogen activators produced by cultured rat granulosa cells.
Knecht M
Endocrinology; 1987 May; 120(5):2174-9. PubMed ID: 3032577
[TBL] [Abstract][Full Text] [Related]
10. Production of plasminogen activators (PAs) in bovine cumulus-oocyte complexes during maturation in vitro: effects of epidermal growth factor on production of PAs in oocytes and cumulus cells.
Park KW; Choi SH; Song XX; Funahashi H; Niwa K
Biol Reprod; 1999 Jul; 61(1):298-304. PubMed ID: 10377062
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth, and morphological alterations.
Amin W; Karlan BY; Littlefield BA
Cancer Res; 1987 Nov; 47(22):6040-5. PubMed ID: 3117361
[TBL] [Abstract][Full Text] [Related]
12. Schwann cell plasminogen activator is regulated by neurons.
Clark MB; Zeheb R; White TK; Bunge RP
Glia; 1991; 4(5):514-28. PubMed ID: 1834568
[TBL] [Abstract][Full Text] [Related]
13. Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells.
Karlan BY; Rivero JA; Crabtree ME; Littlefield BA
Mol Endocrinol; 1989 Jun; 3(6):1006-13. PubMed ID: 2500590
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties.
Mangel WF; Toledo DL; Nardulli AM; Reiner GC; Norman MJ; Katzenellenbogen BS
J Steroid Biochem; 1988; 30(1-6):79-88. PubMed ID: 3386280
[TBL] [Abstract][Full Text] [Related]
15. Cancer cells release a covalent complex containing disulfide-linked domains from urinary plasminogen activator, neural cell adhesion molecule, and haptoglobin alpha and beta chains.
Harvey SR; Nayak SK; Markus G; Ouhammouch M; Hemperly JJ; Dillman RO; Doyle DJ
Arch Biochem Biophys; 1997 Sep; 345(2):289-98. PubMed ID: 9308901
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator activity during decidualization of human endometrial stromal cells is regulated by plasminogen activator inhibitor 1.
Schatz F; Aigner S; Papp C; Toth-Pal E; Hausknecht V; Lockwood CJ
J Clin Endocrinol Metab; 1995 Aug; 80(8):2504-10. PubMed ID: 7629251
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin regulation of tissue-type and urokinase-type plasminogen activators in rat granulosa and theca-interstitial cells during the periovulatory period.
Liu YX; Cajander SB; Ny T; Kristensen P; Hsueh AJ
Mol Cell Endocrinol; 1987 Dec; 54(2-3):221-9. PubMed ID: 3121412
[TBL] [Abstract][Full Text] [Related]
18. Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators.
Levin EG; Loskutoff DJ
J Cell Biol; 1982 Sep; 94(3):631-6. PubMed ID: 6813340
[TBL] [Abstract][Full Text] [Related]
19. Diversity and modulation of plasminogen activator activity in human transitional carcinoma cell lines.
See WA; Yong X; Crist S; Hedican S
J Urol; 1994 Jun; 151(6):1691-6. PubMed ID: 8189598
[TBL] [Abstract][Full Text] [Related]
20. A plasminogen activator inhibitor-2 from a promyelocytic leukemia cell line, PL-21, binds to the carboxy-terminal chain of plasminogen activators.
Takeuchi T; Niiya K; Kubonishi I; Miyoshi I
Thromb Haemost; 1990 Apr; 63(2):259-64. PubMed ID: 2363126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
